Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1975 2
1976 4
1977 1
1979 1
1980 3
1981 2
1982 2
1983 5
1984 13
1985 10
1986 17
1987 4
1988 13
1989 5
1990 17
1991 10
1992 16
1993 14
1994 25
1995 14
1996 21
1997 26
1998 27
1999 28
2000 30
2001 32
2002 30
2003 46
2004 48
2005 47
2006 47
2007 42
2008 59
2009 57
2010 70
2011 53
2012 61
2013 62
2014 63
2015 82
2016 90
2017 82
2018 81
2019 80
2020 103
2021 85
2022 86
2023 73
2024 33

Text availability

Article attribute

Article type

Publication date

Search Results

1,644 results

Results by year

Filters applied: . Clear all
The following term was ignored: %
Page 1
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.
Rajkumar SV. Rajkumar SV. Am J Hematol. 2022 Aug;97(8):1086-1107. doi: 10.1002/ajh.26590. Epub 2022 May 23. Am J Hematol. 2022. PMID: 35560063 Free PMC article.
DISEASE OVERVIEW: Multiple myeloma accounts for approximately 10% of hematologic malignancies. DIAGNOSIS: The diagnosis requires 10% clonal bone marrow plasma cells or a biopsy-proven plasmacytoma plus evidence of one or more multiple myeloma defining …
DISEASE OVERVIEW: Multiple myeloma accounts for approximately 10% of hematologic malignancies. DIAGNOSIS: The diagnosis …
Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review.
Biller LH, Schrag D. Biller LH, et al. JAMA. 2021 Feb 16;325(7):669-685. doi: 10.1001/jama.2021.0106. JAMA. 2021. PMID: 33591350 Review.
The primary treatment for unresectable metastatic CRC is systemic therapy (cytotoxic chemotherapy, biologic therapy such as antibodies to cellular growth factors, immunotherapy, and their combinations.) ...However, for the 35% to 40% of patients with KRAS or NRAS se …
The primary treatment for unresectable metastatic CRC is systemic therapy (cytotoxic chemotherapy, biologic therapy such as an …
Diagnosis and Management of Pituitary Adenomas: A Review.
Tritos NA, Miller KK. Tritos NA, et al. JAMA. 2023 Apr 25;329(16):1386-1398. doi: 10.1001/jama.2023.5444. JAMA. 2023. PMID: 37097352 Review.
Clinically evident pituitary adenomas occur in approximately 1 in 1100 persons. OBSERVATIONS: Pituitary adenomas are classified as either macroadenomas (10 mm) (48% of tumors) or microadenomas (<10 mm). ...First-line therapy for prolactinomas consis …
Clinically evident pituitary adenomas occur in approximately 1 in 1100 persons. OBSERVATIONS: Pituitary adenomas are classified as ei …
Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.
Sekeres MA, Taylor J. Sekeres MA, et al. JAMA. 2022 Sep 6;328(9):872-880. doi: 10.1001/jama.2022.14578. JAMA. 2022. PMID: 36066514 Review.
IMPORTANCE: Myelodysplastic neoplasms (MDS), formerly known as myelodysplastic syndromes, are clonal hematopoietic malignancies that cause morphologic bone marrow dysplasia along with anemia, neutropenia, or thrombocytopenia. ...MDS can be categorized into subtypes …
IMPORTANCE: Myelodysplastic neoplasms (MDS), formerly known as myelodysplastic syndromes, are clonal hematopoietic malignancies …
Clinical management of metastatic colorectal cancer in the era of precision medicine.
Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A. Ciardiello F, et al. CA Cancer J Clin. 2022 Jul;72(4):372-401. doi: 10.3322/caac.21728. Epub 2022 Apr 26. CA Cancer J Clin. 2022. PMID: 35472088 Free article. Review.
Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second most common cause of cancer deaths. Initial clinical presentation as metastatic CRC (mCRC) occurs in approximately 20% of patients. Moreover, up to 50% of patients with loca …
Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second most common cause of cancer deaths. Init …
Diagnosis and Treatment of Breast Cancer in Young Women.
Rossi L, Mazzara C, Pagani O. Rossi L, et al. Curr Treat Options Oncol. 2019 Nov 27;20(12):86. doi: 10.1007/s11864-019-0685-7. Curr Treat Options Oncol. 2019. PMID: 31776799 Review.
Despite the increase of breast cancer incidence with age, approximately 7 to 10% ofwomen diagnosed with breast cancer are younger than the age 40. ...Despite the significant percentage of breast cancer patients younger than age 40, fewclinical studies have specifica …
Despite the increase of breast cancer incidence with age, approximately 7 to 10% ofwomen diagnosed with breast cancer are youn …
Diagnosis and Treatment of Pituitary Adenomas: A Review.
Molitch ME. Molitch ME. JAMA. 2017 Feb 7;317(5):516-524. doi: 10.1001/jama.2016.19699. JAMA. 2017. PMID: 28170483 Review.
OBSERVATIONS: Prevalence of pituitary adenomas ranges from 1 in 865 adults to 1 in 2688 adults. Approximately 50% are microadenomas (<10 mm); the remainder are macroadenomas (10 mm). ...The primary treatment of Cushing disease (hypercortisolism due to ACTH …
OBSERVATIONS: Prevalence of pituitary adenomas ranges from 1 in 865 adults to 1 in 2688 adults. Approximately 50% are microadenomas ( …
Multiple myeloma: 2020 update on diagnosis, risk-stratification and management.
Rajkumar SV. Rajkumar SV. Am J Hematol. 2020 May;95(5):548-567. doi: 10.1002/ajh.25791. Am J Hematol. 2020. PMID: 32212178 Free article. Review.
DISEASE OVERVIEW: Multiple myeloma accounts for approximately 10% of hematologic malignancies. DIAGNOSIS: The diagnosis requires 10% clonal bone marrow plasma cells or a biopsy proven plasmacytoma plus evidence of one or more multiple myeloma defining …
DISEASE OVERVIEW: Multiple myeloma accounts for approximately 10% of hematologic malignancies. DIAGNOSIS: The diagnosis …
Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management.
Ansell SM. Ansell SM. Am J Hematol. 2022 Nov;97(11):1478-1488. doi: 10.1002/ajh.26717. Epub 2022 Sep 19. Am J Hematol. 2022. PMID: 36215668 Free article.
DISEASE OVERVIEW: Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy affecting 8540 new patients annually and representing approximately 10% of all lymphomas in the United States. ...However, newer agents, including brentuximab vedotin and anti-p …
DISEASE OVERVIEW: Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy affecting 8540 new patients annually and representi …
Management of borderline ovarian tumours.
Gershenson DM. Gershenson DM. Best Pract Res Clin Obstet Gynaecol. 2017 May;41:49-59. doi: 10.1016/j.bpobgyn.2016.09.012. Epub 2016 Oct 3. Best Pract Res Clin Obstet Gynaecol. 2017. PMID: 27780698 Review.
Approximately 3000 American women are diagnosed with borderline ovarian tumours annually. ...Prognostic factors include the International Federation of Gynecology and Obstetrics (FIGO) stage, presence of peritoneal implants, micropapillary pattern (for serous histology), m …
Approximately 3000 American women are diagnosed with borderline ovarian tumours annually. ...Prognostic factors include the Internati …
1,644 results